Work

516MO Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies

Year: 2021

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.1038

Authors: H. Park, G. Shapiro, X. Gao, A. Mahipal, J.S. Starr, M. Furqan, P. Singh, A. Ahrorov, D. Hickman, P. Gallacher, E. Attar, M. Awad, S. Das, E.E. Ileana Dumbrava

Institutions: Washington University in St. Louis, Dana-Farber Cancer Institute, Massachusetts General Hospital, Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota), Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida), University of Iowa, University of Iowa Holden Comprehensive Cancer Center, Mayo Clinic Comprehensive Cancer Center (Arizona), The University of Texas MD Anderson Cancer Center, Aprea Therapeutics, Inc. (United States), Dana-Farber/Harvard Cancer Center, Vanderbilt University Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3204862279

FWCI: 0.091

Cites:

Cited by: 1

Related to: 10